Insights
Insights From Our Experts
Articles
What’s Really Driving the Direct-to-Patient Boom?
Once viewed as an emerging channel, Direct-to-Patient (DTP) models are increasingly becoming a core component of commercial strategy as life sciences manufacturers look for new ways to improve patient access, reduce friction, and create more direct relationships with…
Why “Fully Staffed” Field Sales Teams Still Miss Revenue Targets and How Pharma Can Fix It
“Fully staffed” doesn’t always mean fully effective. Our own Krista Pinto, President of Deployment Solutions, shares why traditional field sales team models are no longer sufficient in today’s commercial landscape and what pharma leaders must do to evolve in a recent interview with Pharmaceutical…
AI Leadership Will Be Earned, Not Claimed
In pharma, AI isn’t defined by what it can do. It’s defined by what it can prove. AI adoption is no longer a question of potential. It is a question of performance. Most pharmaceutical organizations are…
EVERSANA’s Sustainability Report: Our Commitment to a Healthier World
Advancing life sciences and creating a healthier world extends beyond the services we deliver. It is reflected in how we operate as a responsible partner to our clients, our people, and the communities we serve. That’s why we’re excited…
The Evolving Role of Pharma 3PLs To Drive Value & Impact
Danny Williams, President of Channel Management & 3PL at EVERSANA, recently sat down Pharmaceutical Commerce for a series of interviews on the state of pharm 3PLs and logistics. He discussed the role of today’s logistics partners…
The Real Cost of Delayed Pharmacovigilance (PV) Launch Readiness
What is the real cost of delayed Pharmacovigilance (PV) launch readiness? Most pharmaceutical launch delays and failures are not driven by clinical setbacks but are caused by hidden gaps in commercial compliance readiness. There are four predictable, high-stakes moments…
Avoiding the Top 3 Pharmacovigilance Mistakes
FDA approval is a monumental milestone for any emerging pharma or biotech company. However, for first-time sponsors, ringing the bell on approval is just the beginning. The transition into maintaining an operationally critical, inspection-ready Pharmacovigilance (PV) function is a…
What’s Trending in Oncology? A Discussion Following ASCO 2026 with Anne Marie Robertson
Following ASCO 2026, one message is clear: innovation in oncology is accelerating and the complexity of bringing these therapies to market is evolving just as quickly. In a recent Q&A with Pharmaceutical Executive, Anne Marie Robertson,…
Winning in the EU JCA Era: Why Proactive Intelligence Will Define Market Access Success
The EU JCA Is Changing the Rules of Market Access The EU Joint Clinical Assessment (JCA) is not simply another regulatory milestone; it represents a fundamental transformation in how clinical evidence will be evaluated, aligned, and…
Why Humans Must Be Part of the Bigger AI Picture
As AI reshapes how work gets done across industries, all organizations including life sciences are being challenged to balance speed, scale, and innovation with something equally critical: trust. Faruk Capan, Chief Innovation Officer at EVERSANA, explores…